Miss our recent webinar with Dr. Andy Lewis, Chief Scientific Officer, and Dr. Andrew Parker, Senior Drug Development Consultant? Watch it now on-demand to hear about the #biopharmaceutic and CMC considerations for oral GLP-1 #peptide therapeutics: https://lnkd.in/eXnxuiFd
Quotient Sciences
Pharmaceutical Manufacturing
Nottingham, Nottinghamshire 20,037 followers
Molecule to cure. Fast.
About us
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast. We employ over 1,300 staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need. We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.
- Website
-
https://bit.ly/3u9sI6l
External link for Quotient Sciences
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Nottingham, Nottinghamshire
- Type
- Privately Held
- Specialties
- CDMO, Formulation Development, Phase I & II Clinical Trial Manufacturing, Translational Pharmaceutics, High Potency Handling, Real-time Adaptive Manufacturing, Commercial Manufacturing, Solubility Enhancement, Modified Release, Pediatric Formulation Development, CRO, First-in-Human, Clinical Pharmacology, Relative Bioavailability, Pharmacokinetics, Drug-Drug Interaction, Human ADME / 14C, Data Sciences, Modelling & Simulation, Drug Substance, Scintigraphy, Bioanalysis, Isotope Labelling, Clinical Trial Supplies, Bioequivalence, Healthy Volunteer Studies, Proof-of-Concept, Drug Development, and Dosage Form Development
Products
Locations
Employees at Quotient Sciences
Updates
-
Our offices celebrated #Halloween last week with some fun festivities including pumpkin carving, door decorating contests, and treats. Check out some of the photos here!
-
-
-
-
-
4
-
-
#QuotientSciences has been recognized as a finalist in two categories of Fierce Biotech's 2024 #FierceCROAwards: Excellence in Client Service and Partnership and Innovative Solutions in Drug Development. These awards celebrate exceptional achievements and innovations by CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services. Read more: https://lnkd.in/eFtXv5Tv
-
-
Our CEO, Thierry Van Nieuwenhove, recently spoke with European Pharmaceutical Manufacturer about how #QuotientSciences is innovating to meet the growing demand for more personalized medicine and tracking towards #sustainability goals: https://bit.ly/3Bu7N4B
-
-
Dr. Valeria Ciarnelli, Senior Director of Product Development, and Dr. Andrew Parker, Senior Drug Development Consultant, discuss considerations when navigating the pre-clinical to clinical transition, regulatory expectations and needs of enabling technologies for poorly soluble molecules. Watch their presentation on-demand: https://lnkd.in/g9vcKMaP
-
Latest news: We are proud to announce that we have been named a finalist in two categories of Fierce Biotech's 2024 #FierceCROAwards. The two categories we have been named a finalist include Excellence in Client Service and Partnership and Innovative Solutions in Drug Development.
The Top CROs Leading the Way in Clinical Research – Finalists Announced https://loom.ly/7x12MGw These Contract Research Organizations (CROs) have distinguished themselves through outstanding contributions to clinical research and advancements in life sciences. Recognized for their leadership, innovation, and commitment to excellence, our finalists exemplify the highest standards in the industry. We invite you to explore the list of this year's exceptional finalists and join us in recognizing their impactful work. View the full list here. 🔗 https://loom.ly/7x12MGw #FierceCROAwards #ClinicalResearch #LifeSciences
-
-
Dr. Asma Patel, Vice President of Integrated Development Services, speaks on how #AI and machine learning are contributing to rapid innovation in the #pharmaceutical industry in this #article with Pharmaceutical Technology: https://bit.ly/3XXJWTC
-
-
Dr. Helen Baker, Director of Formulation Design, speaks on how ASAPprime® works at different stages of the development process and how customers can benefit from adding on analysis to their next drug program: https://lnkd.in/eXyzgUDp
-
-
Latest News: Medicines for Malaria Venture and Quotient Sciences have begun the first #clinicaltrial at Quotient Sciences' Nottingham, UK facility for a long-acting injectable (LAI) preventive compound for malaria, MMV371. The trial marks a significant step toward preventing #malaria in endemic regions. Read more: https://lnkd.in/eaHj3h4s
Quotient Sciences and MMV Begin First Clinical Trial for Preventive Malaria Compound
-
Dr. Vanessa Zann, Executive Drug Development Consultant, hosted an informative seminar last week during #AAPS focusing on our #TranslationalPharmaceutics® platform and its applications, highlighting how it can help integrate #drugproduct formulation development, on-demand GMP manufacture, and clinical testing to accelerate #drugdevelopment programs. Thanks to everyone who attended! To learn more about Dr. Zann's work visit: https://lnkd.in/eYhSZMZW
-